Insulin Glargine

Known as: INSULIN,GLARGINE,HUMAN/rDNA, Glargine, Insulin, Insulin, Glycyl(A21)-Arginyl(B31,B32) 
A recombinant human insulin analog with long-acting, blood glucose-lowering activity. Insulin glargine, like regular types of human insulin… (More)
National Institutes of Health

Related topics

Related topics

19 relations
1.5 ML Insulin Glargine 300 UNT/ML Pen Injector [Toujeo]3 ML Insulin Glargine 100 UNT/ML Pen Injector [Lantus]Decreased Lipolysis [PE]Diabetes Mellitus, Insulin-Dependent
(More)

Narrower (3)

HOE 901LY2963016 insulin glargineLantus

Broader (1)

Hypoglycemic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Basal insulin and cardiovascular and other outcomes in dysglycemia.
BACKGROUND The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events… (More)
  • table 1
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
Aims/hypothesis The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
OBJECTIVE Insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
The aim of this randomized double-blind study was to compare the within-subject variability of the glucose-lowering effect of a… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
OBJECTIVE To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Context Insulin glargine is a long-acting insulin preparation that has recently become available. Its optimal role in the… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
OBJECTIVE Insulin glargine (21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin) is a biosynthetic insulin analog with a prolonged… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin…
To compare the pharmacokinetics/dynamics of the long-acting insulin analog glargine with NPH, ultralente, and continuous… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
In recent years, analogs of human insulin have been engineered with the aim of improving therapy for people with diabetes. To… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?